Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exploring the genetic diversity of the 16S rRNA gene of <i>Akkermansia muciniphila</i> in IBD and IBS.
|
31850811 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Epi-IBD study is a prospective population-based cohort of 1289 IBD patients diagnosed in centers across Europe.
|
30562421 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusions:</b> The self-monitoring of IBD activity with a combination of a rapid fecal calprotectin home test and a symptom questionnaire provides an option for individualized care for IBD patients.
|
31264494 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hispanic children were more likely to be diagnosed with UC (P < 0.01) and unclassified IBD (IBD-U) (P < 0.03) compared with other races/ethnicities.
|
31587061 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to determine the impact of IBD diagnosis on fitness levels and to assess the levels of engagement in physical activity and fatigue in IBD patient before and after diagnosis.
|
30561568 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Abbreviations</b>: CBA: Controlled Before and After; GSD: Government Service Delivery; IWDSSD: International Drinking-Water, Supply and Sanitation Decade (IDWSSD); KAP: Knowledge, Attitudes and Practices; IBD: Irritable Bowel Diseases; MDG: Millennium Development Goals; NTD: Neglected Tropical Diseases; PSSD: Private Sector Service Delivery; SDG: Sustainable Development Goals; SSA: Sub Saharan Africa; SODIS: Solar Disinfection System; STH: Soil Transmitted Helminths; RCT: Randomised Control Trial; WASH: Water Sanitation and Hygiene; WHO: World Health Organization.
|
30545246 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted an all-age multiparameter search strategy using inpatient IBD international classification of disease (ICD-10) coding (K50/51)(1997-2018), IBD pathology coding (1990-2018), primary and secondary care prescribing data (2009-2018) and a paediatric registry, (1997-2018) to identify 'possible' IBD cases up to 31/08/2018.
|
31300515 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The costs of medical care for insurees with IBS in the year of their initial diagnosis were higher than those of other insurees without the diagnosis of IBD (€ 3770 vs. € 2788) and rose in each of the eight years preceding the initial diagnosis.
|
31431234 |
2019 |
Irritable Bowel Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eight studies were included in the meta-analyses (6 on irritable bowel syndrome [IBS] and two on inflammatory bowel disease [IBD]).
|
29901820 |
2018 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similar correlations may link IBS as a precursor to IBD and possibly other conditions which are geographically connected with IBD.
|
29317064 |
2018 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Half of IBD specialists would provide pre-travel advice to IBD patients and two-thirds would advise continuing all IBD medications even when travelling to TB-endemic areas.
|
30215692 |
2018 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Iron deficiency is a common complication in patients with IBD and oral iron therapy is suggested to exacerbate IBD symptoms.
|
26848182 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Resource use for IBD management was itemized for attributable costs (AUD) among all IBD patients over a 12-month period at an Australian hospital.
|
28509590 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we aimed to assess the anti-inflammatory effect and the mechanism of action of sialorphin, the natural blocker of the endogenous opioid peptide-degrading enzymes neprilysin [NEP] and aminopeptidase N [APN], in mouse models of IBD and the changes in the expression of these enzymes in IBD patients.
|
28333341 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most appreciated were the topics brain imaging of gut activity, the role of the gut microbiota, the pharmacology of gut functions, the IBS-IBD interrelation, the new Rome IV criteria, the role of gas, and the placebo response in functional disorders.
|
27997070 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two matched pools were generated: patients with IBD and CDI vs non-IBD patients with CDI [matched for age, sex and date] and patients with IBD and CDI vs IBD patients without CDI [matched for age and IBD type].
|
27302972 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the rHVT/IBD (US10) elicited lower levels of virus-neutralizing (VN) antibodies compared to the other constructs. rHVT/IBD (UL3-4) and rHVT/IBD (UL45-46) appeared to be similar in their ability to elicit VN antibodies.
|
27942974 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In both IBD and non IBD patients all these causes became more clinically important with advancing age, with the commonest neoplastic cause of death being lung cancer rather than gastrointestinal cancers.
|
28453767 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
After adjustment for age, gender, and stage at diagnosis, the excess hazard of death after CRC diagnosis was 1.7 times higher in IBD than in non-IBD patients (95% CI 1.27-2.33).
|
28050782 |
2017 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant differences in ACK1 expression were found between UC and CD, or between IBD and non-IBD conditions (P>0.05).
|
27926694 |
2016 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
TI biopsies from paediatric inflammatory bowel disease [IBD] subsets [Crohn's disease [CD; n = 13] and UC [n = 10]], and non-IBD disease controls [n = 12] were histologically graded, and alcian blue/periodic acid-Schiff stained biopsies were quantified.
|
26660940 |
2016 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Post-infectious IBS (PI-IBS) and inflammatory bowel disease-associated IBS (IBD-IBS) represent a considerable subset of IBS cases.
|
23066308 |
2012 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In all, 2195 subjects (361 children (inflammatory bowel disease [IBD] diagnosis <17 years), their parents (n = 634), 855 adult IBD patients, and 345 controls were genotyped.
|
18088053 |
2008 |
Irritable Bowel Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare phenotype and course of disease between IBD patients with a first-degree relative with IBD and sporadic cases in a population-based cohort followed prospectively for 5 yr.
|
17573793 |
2007 |